CLINICAL LASERTHERMIA SYSTEMS AB Clinical Laserthermia Systems AB Stock
Equities
CLS B
SE0022049920
Advanced Medical Equipment & Technology
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.95 SEK | -4.76% |
|
-15.01% | -45.83% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2023 | 8.27M 765K | Sales 2024 * | 39M 3.6M | Capitalization | 123M 11.39M |
|---|---|---|---|---|---|
| Net income 2023 | -79M -7.3M | Net income 2024 * | -54M -4.99M | EV / Sales 2023 | 20.5 x |
| Net cash position 2023 | 14.88M 1.37M | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 3.16 x |
| P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-
| Employees | 14 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 8.01% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -4.76% | ||
| 1 week | -15.01% | ||
| Current month | -15.01% | ||
| 1 month | -7.49% | ||
| 3 months | -31.42% | ||
| 6 months | -37.45% | ||
| Current year | -45.83% |
1 week
14.50
17.59
1 month
14.5022.00
Current year
14.4037.60
1 year
14.40217.00
3 years
14.401 292.00
5 years
14.402 710.00
10 years
14.405 180.00
| Managers | Title | Age | Since |
|---|---|---|---|
Dan J. Mogren
CEO | Chief Executive Officer | - | - |
| Founder | 75 | 06-03-08 | |
| Chief Tech/Sci/R&D Officer | - | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 69 | 09-12-31 | |
Hans von Celsing
CHM | Chairman | 74 | 10-12-31 |
| Founder | 75 | 06-03-08 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 14.95 | -4.76% | 26 188 |
| 24-05-06 | 15.7 | -3.40% | 21,933 |
| 24-05-03 | 16.25 | -0.67% | 23,611 |
| 24-05-02 | 16.36 | -6.99% | 26,325 |
| 24-04-30 | 17.59 | +1.39% | 11,730 |
Delayed Quote Nasdaq Stockholm, May 07, 2024 at 10:44 am EDT
More quotes
Clinical Laserthermia Systems AB is a Sweden-based company active in the medical equipment industry. The Company develops and markets a product for the treatment of solid cancer tumors. The product is based on Immunostimulating Laser Thermo Therapy (imILT). imILT method can be used for all tumors in solid organ and the potential market is considerable. Examples of tumors which are suitable for treatment are those found in liver, breast, lung, prostate, kidney, pancreas and thyroid. Clinical Laserthermia Systems AB's treatment system consists of two main parts: a mobile laser device and a sterile patient unit for single use. The Company's product is intended for medical professionals within surgical oncology or interventional radiology within oncology. In April 2014, the Company announced the establishment of a subsidiary in the United States.
Calendar
2024-05-16
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -45.83% | 11.41M | |
| +20.72% | 1.01B | |
| -25.29% | 237M | |
| -28.43% | 84.13M |
- Stock Market
- Equities
- CLS B Stock